摘要
新的个体化治疗程序在肿瘤学中的有效性基于这样的事实,即某些肿瘤表现出特定的分子特征。 更详细地说,患者的肿瘤组织应显示特定的生物标志物,最常见的是特定的基因改变和/或明确蛋白质的下/过表达,其可能是其各自药物的靶标。免疫组织化学和分子分析,通常包括检查来自组织或液体的核酸,是定义肿瘤状态的常用测试。 本综述着重于病理学家在仔细控制预分析程序和标准操作程序方面的作用,这是达到可靠和可重复结果的关键先决条件。总结了六种靶向治疗的典型应用,其中病理诊断起着重要的作用。传统和新一代测序也从病理学家的角度来解决,以及重要性病理学家在个性化医学时代转向更准确定义疾病风险和治疗反应的预测。
关键词: 目标疗法,生物标志物,病理学家的观点,免疫组织化学,FFPE组织,分子分析,传统测序,下一代测序
图形摘要
Current Cancer Drug Targets
Title:Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Volume: 18 Issue: 5
关键词: 目标疗法,生物标志物,病理学家的观点,免疫组织化学,FFPE组织,分子分析,传统测序,下一代测序
摘要: The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features.
More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor.
This review focuses on the pathologist’s role in carefully controlling pre- analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist's perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.
Export Options
About this article
Cite this article as:
Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009618666171129145703
DOI https://dx.doi.org/10.2174/1568009618666171129145703 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Folate Targeted Solid Lipid Nanoparticles of Simvastatin for Enhanced Cytotoxic Effects of Doxorubicin in Chronic Myeloid Leukemia
Current Nanoscience Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets Genetic Surgery - A Right Strategy to Attack Cancer
Current Gene Therapy New Scope of Targeted Therapies in Lung Carcinoma
Mini-Reviews in Medicinal Chemistry Selenium Compounds and Apoptotic Modulation: A New Perspective in Cancer Therapy
Mini-Reviews in Medicinal Chemistry 3-Bromopyruvic Acid, A Hexokinase II Inhibitor, is an Effective Antitumor Agent on the Hepatoma Cells : in vitro and in vivo Findings
Anti-Cancer Agents in Medicinal Chemistry Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery MicroRNA: Biogenesis, Function and Role in Cancer
Current Genomics A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies
Current Pharmaceutical Design Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm
Current Gene Therapy Gene Therapy for Lung Diseases Development in the Vector Biology and Novel Concepts for Gene Therapy Applications
Current Molecular Medicine Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials Patent Selections
Recent Patents on Biomarkers Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Leukotriene A4 Hydrolase as a Target for Cancer Prevention and Therapy
Current Cancer Drug Targets